Document is current

Article History

Accepted: 29 May 2024

First Online: 22 July 2024

Competing interests

: P.K. has served as a consultant, advisory board member or speaker for Abbott, Angelini, Aquestive, Arvelle Therapeutics, Aucta Pharmaceuticals, Dr Reddy’s, Eisai, Jazz Pharmaceuticals, Neurelis, Neurona, Paladin, SK Life Science, Sunovion, UCB Pharma, UNEEG, UniQure, is a member of the Medical Advisory Board of Stratus and of the Scientific Advisory Board of OB Pharma, is on DSMB of Neurona Therapeutics for the NRTX-1001 trial, is co-founder and the CEO of PrevEp, and has received research support from CURE/Department of Defense and from the NIH/SBIR. M.K. has served as a consultant, advisory board member or speaker for Angelini, Arvelle Therapeutics, Bial, Eisai, GE, Novartis, Jazz Pharmaceuticals, UCB Pharma, is co-founder of PrevEp, has received research support from Epilepsy Research UK, the Epilepsy Society, MRC and Wellcome Trust. R.M.K. is employed by Angelini Pharma. W.L. has served as a consultant or advisory board member for AC Immune, Addex, Atlas Venture, Angelini, Axonis, Boehringer Ingelheim, Celltech, Clexio, Cogent, Idorsia, Lundbeck, ND Capital, Novartis, Ovid, Pragma, and Selene, is co-founder and the CSO of PrevEp, and has received research support from the German Research Foundation, the European Union and the NINDS/NIH.